Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC-T cells
- Development stage
- Preclinical
- Lead developer
- Guangzhou Municipality Tianhe Nuoya Bio-engineering
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TAC-T cells are a novel type of engineered T-cell therapy designed for cancer treatment, particularly solid tumors. This therapy utilizes a T-cell antigen coupler (TAC) receptor, which differs from traditional CAR-T cells by co-opting the endogenous T-cell receptor (TCR) signaling pathway. This mechanism aims to achieve robust anti-tumor activity while potentially offering an improved safety profile by mimicking natural T-cell activation and reducing off-target toxicities and cytokine release syndrome. The specific TAC-T cells in question are engineered to target Nectin4/NKG2DL and FAP, and are further modified to secrete cytokines such as Interleukin-7 (IL7), Chemokine (C-C motif) ligand 21 (CCL21), and Interleukin-12 (IL12) to enhance their anti-tumor efficacy and overcome the immunosuppressive tumor microenvironment.
- Other names
- T-cell antigen coupler T cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)CD3 (T-cell surface glycoprotein CD3)PVRL4 (Nectin cell adhesion molecule 4)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on TAC-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC-T cells.